Page 1263 - Basic _ Clinical Pharmacology ( PDFDrive )

Index 1249

migraine headache prophylaxis using, on gut, bone, and kidney, 778t drug interactions of, 616, 616t
291 hyperparathyroidism treated with, 784 mechanism of action of, 610t,
Vernakalant, 239t–240t, 247, 251t hypocalcemia treated with, 614–615, 615f
Verubecestat, 1063 784 reversal of action of, 616
Very-low-density lipoproteins (VLDLs), hypoparathyroidism treated with, 784 toxicity of, 615
165, 626, 627, 628f intestinal osteodystrophy treated with, Water, superoxidized, 900
Vesamicol, 93 785 Weak acid
Vesicle-associated membrane proteins nutritional deficiency/insufficiency of, examples of, 10t
(VAMPs), 93, 94f 785 ionization of, 9–10
Vesicle-associated transporter (VAT), 93, Vitamin D 3 Wearing-off, 497
94f on bone homeostasis, 773, 776f Wernicke-Korsakoff syndrome,
Vesicular acetylcholine transporter vitamin D deficiency/insufficiency 400, 403
(VAChT), 93 treated with, 785 West’s syndrome, 410, 431
Vesicular glutamate transporter (VGLUT), Vitamin D 2 , for vitamin D deficiency/ White thrombi, 609
375 insufficiency, 785 Whole bowel irrigation, for iron toxicity,
Vesicular monoamine transporter (VMAT), Vitamin D preparations, 789t 596
95 chronic kidney disease treated with, Wilson’s disease, 507
Vesicular proteoglycan (VPG), 94 785–786 Withdrawal, 576–578. See also specific
Vestibular disturbances, 274 forms of, available, 790t substances
Vigabatrin, 431, 433t, 437t Vitamin K from alcohol, 403, 403f, 406t, 407t
Vilanterol bleeding disorders treated with, 614f, from opioids, 559
asthma treated with, 351, 362t 621 from sedative-hypnotics, 393
chronic obstructive pulmonary disease structure of, 621 Withdrawal syndrome, 559, 565, 575
treated with, 152 Vitamin K 1 Wolff-Chaikoff block, 689
Vilazodone, 540t, 541, 549 structure of, 614f Wolff-Parkinson-White syndrome, 234
Vildagliptin, 763, 769t warfarin reversal using, 616 Wong-Baker scale, 562
Vinblastine Vitamin K epoxide reductase complex Worm infections, 938–947, 939t. See also
cancer treated with, 961–962, 962t subunit 1 (VKORC1) Antihelminthics
immunosuppressive uses of, 989 alleles of, 77t Wuchereria bancrofti, 941
Vincristine polygenic effects in, 79t, 85–86
cancer treated with, 962t, 963 VKORC1, 77t, 79t, 85–86 X
immunosuppressive uses of, 989 VMAT transporter, 8t Xanthine oxidase inhibitors, 83
Vinorelbine, 962t, 963 Voglibose, 761, 768t Xanthines, 352f. See also Methylxanthine
Viruses, 863 Voltage-gated channels, 30, 369f, 369–370. drugs
cancer from, 948–949 See also specific types Xeljanz, 987
replication of, 863, 864f Volume of distribution (V), 42 Xenobiotics, 56
Vismodegib, 1085 initial predictions of, 54 biotransformation of. See
Visual analog scale (VAS), 562 revising individual estimates of, 54 Biotransformation, drug
Vitamin B 1 , 403. See Thiamine on target concentration, 52 definition of, 3
Vitamin B 12 deficiency Vomiting, 1103, 1104f X-linked agammaglobulinemia, 984
description of, 594t, 596, 598 Vonicog alfa, 622 X-linked hypophosphatemia,
megaloblastic anemia from, von Willebrand disease, 622t, 623 787–788
591, 607 Voriconazole, 857f, 858t, Xylene, 1010
Vitamin B 12 therapy, for vitamin B 12 858–859, 861t
deficiency, 596–598, 597f Vorinostat, dermatologic, 1085 Y
chemistry of, 596 Vortioxetine, 540t, 542t, 547, 549, Yellow fever vaccine, 1178t
clinical pharmacology of, 594t, 598 549t. See also 5-HT receptor Yervoy, 992
cyanocobalamin, 596, 598, 606t modulators YKP3089, 435
hydroxycobalamin, 596, 598, 606t v-SNAREs, 94 Yohimbine, 160, 170t
pharmacodynamics of,
596–598, 597f W Z
pharmacokinetics of, 596 Warfarin, 614–616 Zafirlukast, 332. See also Leukotriene
preparations available, 607t administration and dosage of, receptor antagonists
Vitamin D 615–616 asthma treated with, 336,
bone homeostasis and, 773, 774f, chemistry and pharmacokinetics of, 356–357, 362t
775–777, 776f, 777t, 789t 614, 614f structure of, 356f
chronic kidney disease treated with, CYP2C9 and VKORC1 polymorphisms Zaleplon, 382, 383f, 385t, 389, 391, 394t.
785–786 on, 79t, 85–86 See also Hypnotics